home / openregs / legislation

legislation: 106-hr-4764

Congressional bills and resolutions from Congress.gov, filtered to policy areas relevant to environmental, health, agriculture, and wildlife regulation.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

bill_id congress bill_type bill_number title policy_area introduced_date latest_action_date latest_action_text origin_chamber sponsor_name sponsor_state sponsor_party sponsor_bioguide_id cosponsor_count summary_text update_date url
106-hr-4764 106 hr 4764 To require the United States Trade Representative to enter into negotiations to eliminate price controls imposed by certain foreign countries on prescription drugs. Foreign Trade and International Finance 2000-06-27 2000-06-27 Referred to the House Committee on Ways and Means. House Rep. Ewing, Thomas W. [R-IL-15] IL R E000282 2 Directs the United States Trade Representative (USTR) to enter into negotiations with the Governments of the other G-8 countries (Canada, France, Germany, Great Britain, Italy, Japan, Russia, and the United States) in order to achieve their agreement to eliminate price controls on innovative medicines and the unfair trade practices that result from the application of price controls.Declares that, if within 12 months negotiations have not achieved such objectives, the USTR shall recommend to Congress the most effective measures (including those specified by the Trade Act of 1974) for eliminating the disparity between the price of prescription drugs in the United States and the price of prescription drugs in the other G-8 countries, with the goal of reducing the price of prescription drugs for U.S. consumers.Requires recommended measures to be of a nature and amount that fully reflect the economic harm inflicted on patients and health care in the United States, and the harm inflicted on the U.S. economy when countries pay the country specific marginal costs of prescription drugs and let the United States cover the research and development costs of innovative prescription drugs. 2025-01-02T17:14:31Z  

Links from other tables

  • 3 rows from bill_id in legislation_actions
  • 19 rows from bill_id in legislation_subjects
  • 2 rows from bill_id in legislation_cosponsors
  • 0 rows from bill_id in cbo_cost_estimates
Powered by Datasette · Queries took 0.322ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API